



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Bexarotene (Oral) Prior Authorization Policy

- Targretin® (bexarotene capsules – Bausch Health, generic)

**REVIEW DATE:** 11/22/2023

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Oral bexarotene is indicated for the treatment of **cutaneous manifestations of cutaneous T-cell lymphoma** in patients who are refractory to at least one prior systemic therapy.<sup>1</sup>

### Guidelines

The National Comprehensive Cancer Network (NCCN) Primary Cutaneous Lymphomas guidelines (version 1.2023 – January 5, 2023) recommend oral bexarotene as an option for the treatment of cutaneous lymphomas (e.g., mycosis fungoides, Sézary syndrome, anaplastic large cell lymphoma [ALCL], lymphomatoid papulosis), as initial therapy and for relapsed/refractory cases. NCCN notes there are limited data from case reports demonstrating efficacy of oral bexarotene for the treatment of ALCL with multifocal lesions and for lymphomatoid papulosis with extensive lesions.

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of bexarotene capsules. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with bexarotene capsules as well as the monitoring required for adverse events and long-

term efficacy, approval requires bexarotene capsules to be prescribed by or in consultation with a physician who specializes in the condition being treated.

- **Targretin® (bexarotene capsules – Bausch Health, generic)**

**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

#### **FDA-Approved Indication**

- 1. Cutaneous T-Cell Lymphoma.** Approve for 1 year if the patient meets the following (A and B):
  - A)** Patient has cutaneous manifestations/lesions; AND
  - B)** The medication is prescribed by or in consultation with an oncologist or a dermatologist.

#### **CONDITIONS NOT COVERED**

**Targretin® (bexarotene capsules – Bausch Health, generic)**  
**is(are) considered experimental, investigational or unproven for ANY other use(s)**

#### **REFERENCES**

1. Targretin® capsules [prescribing information]. Bridgewater, NJ: Bausch Health; April 2020.
2. The NCCN Primary Cutaneous Lymphomas Clinical Practice Guidelines in Oncology (version 1.2023 – January 5, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 20, 2023.
3. The NCCN Drugs & Biologics Compendium. © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on November 20, 2023. Search terms: bexarotene.

#### **HISTORY**

<b>Type of Revision</b>	<b>Summary of Changes</b>	<b>Review Date</b>
Annual Revision	Policy name is changed from Oncology – Targretin (Oral) PA to Oncology – Bexarotene (Oral) PA with Step Therapy. No criteria changes.	11/02/2022
Selected Revision	<b>Cutaneous T-Cell Lymphoma:</b> Criterion “Patient has cutaneous manifestations” is changed to “Patient has cutaneous manifestations/lesions”. The requirements for use of generic bexarotene capsules before brand Targretin was removed. Policy name is changed to remove “with Step Therapy” from the title.	01/25/2023 Effective 04/15/2023
Annual Revision	No criteria changes	11/22/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna